Kimball Electronics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Kimball Electronics reported Q1 FY2027 net sales of $390.8M (+7% YoY, +5% QoQ), with organic growth of 3% and Medical vertical up 14% (9% organic). The company acquired Helvoet Polymer Technologies (medical CDMO, contributed $12.4M in Q1 sales) and reiterates FY2027 guidance for sales at high end of $1,535–$1,560M range with 4.4%–4.7% adjusted operating margin. Debt stands at $235.7M, cash at $72.8M; company repurchased 127,000 shares for $3.1M.
Why this rating
Modest top-line growth (+7% reported, +3% organic) within guidance range; Helvoet tuck-in supports medical strategy but small contributor (~$12.4M, ~1.8% of quarterly revenue). No material change to outlook. Routine quarterly execution.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.